Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 26 | 2024 | 2329 | 3.840 |
Why?
|
Carcinoma, Hepatocellular | 15 | 2024 | 2291 | 3.000 |
Why?
|
Liver Neoplasms | 15 | 2024 | 4308 | 2.390 |
Why?
|
End Stage Liver Disease | 8 | 2023 | 352 | 2.260 |
Why?
|
Hepatitis C | 8 | 2021 | 1579 | 1.540 |
Why?
|
Hepacivirus | 8 | 2021 | 1330 | 1.220 |
Why?
|
Hepatitis C, Chronic | 5 | 2021 | 1018 | 1.040 |
Why?
|
Antiviral Agents | 10 | 2021 | 3039 | 0.950 |
Why?
|
Protoporphyria, Erythropoietic | 3 | 2023 | 55 | 0.860 |
Why?
|
Liver Diseases | 5 | 2023 | 1297 | 0.770 |
Why?
|
Porphyrias, Hepatic | 1 | 2020 | 6 | 0.750 |
Why?
|
alpha-Fetoproteins | 3 | 2021 | 222 | 0.680 |
Why?
|
Aspartate Aminotransferases | 1 | 2020 | 414 | 0.640 |
Why?
|
Peritoneal Fibrosis | 1 | 2017 | 9 | 0.600 |
Why?
|
Alanine Transaminase | 1 | 2020 | 601 | 0.590 |
Why?
|
Tissue Donors | 4 | 2020 | 2331 | 0.580 |
Why?
|
Heart Murmurs | 1 | 2017 | 92 | 0.560 |
Why?
|
Hepatitis, Autoimmune | 3 | 2024 | 172 | 0.560 |
Why?
|
Nevus, Blue | 1 | 2017 | 43 | 0.560 |
Why?
|
Protein Kinase C | 2 | 2014 | 1202 | 0.540 |
Why?
|
Peritoneal Dialysis | 1 | 2017 | 159 | 0.530 |
Why?
|
Hypertension, Portal | 2 | 2014 | 226 | 0.490 |
Why?
|
Portal Vein | 2 | 2014 | 431 | 0.480 |
Why?
|
Nausea | 1 | 2017 | 679 | 0.470 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2014 | 438 | 0.470 |
Why?
|
Vomiting | 1 | 2017 | 651 | 0.460 |
Why?
|
Acetaminophen | 4 | 2019 | 555 | 0.440 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2017 | 369 | 0.420 |
Why?
|
AMP-Activated Protein Kinases | 2 | 2014 | 597 | 0.410 |
Why?
|
Waiting Lists | 6 | 2024 | 764 | 0.400 |
Why?
|
Graft Survival | 6 | 2024 | 3820 | 0.400 |
Why?
|
Liver | 6 | 2021 | 7512 | 0.380 |
Why?
|
Abdominal Pain | 1 | 2017 | 1070 | 0.370 |
Why?
|
RNA, Viral | 2 | 2018 | 2838 | 0.340 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2018 | 9277 | 0.340 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2017 | 955 | 0.330 |
Why?
|
Colon | 1 | 2017 | 1791 | 0.320 |
Why?
|
Genetic Diseases, X-Linked | 2 | 2023 | 386 | 0.320 |
Why?
|
Necrosis | 2 | 2014 | 1610 | 0.310 |
Why?
|
Kidney Failure, Chronic | 2 | 2018 | 2477 | 0.300 |
Why?
|
Decision Support Techniques | 1 | 2018 | 1998 | 0.300 |
Why?
|
Hydrogen Peroxide | 3 | 2008 | 730 | 0.300 |
Why?
|
Hepatocytes | 3 | 2014 | 1231 | 0.290 |
Why?
|
Registries | 3 | 2019 | 8207 | 0.280 |
Why?
|
Living Donors | 3 | 2022 | 641 | 0.280 |
Why?
|
Baltimore | 4 | 2018 | 231 | 0.250 |
Why?
|
Liver Cirrhosis, Biliary | 2 | 2023 | 108 | 0.250 |
Why?
|
Middle Aged | 27 | 2024 | 220584 | 0.240 |
Why?
|
Multienzyme Complexes | 1 | 2008 | 666 | 0.240 |
Why?
|
Hepatitis B | 2 | 2021 | 702 | 0.230 |
Why?
|
Hepatitis, Chronic | 1 | 2024 | 52 | 0.230 |
Why?
|
United States | 12 | 2024 | 72272 | 0.220 |
Why?
|
Hepatitis, Viral, Human | 1 | 2024 | 141 | 0.220 |
Why?
|
Hepatitis C Antibodies | 2 | 2020 | 146 | 0.220 |
Why?
|
5-Aminolevulinate Synthetase | 1 | 2023 | 64 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.210 |
Why?
|
Dermatitis, Phototoxic | 1 | 2022 | 17 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.210 |
Why?
|
Retrospective Studies | 20 | 2024 | 80566 | 0.200 |
Why?
|
Recurrence | 7 | 2018 | 8426 | 0.190 |
Why?
|
Tissue and Organ Procurement | 2 | 2020 | 962 | 0.190 |
Why?
|
Male | 29 | 2024 | 360358 | 0.190 |
Why?
|
Aminoisobutyric Acids | 1 | 2021 | 39 | 0.190 |
Why?
|
Humans | 46 | 2024 | 760617 | 0.180 |
Why?
|
Mitochondria, Liver | 2 | 2014 | 190 | 0.180 |
Why?
|
Donor Selection | 3 | 2019 | 232 | 0.180 |
Why?
|
Policy | 1 | 2023 | 506 | 0.170 |
Why?
|
Leucine | 1 | 2021 | 548 | 0.170 |
Why?
|
Carbamates | 1 | 2021 | 191 | 0.170 |
Why?
|
Cyclopropanes | 1 | 2021 | 432 | 0.170 |
Why?
|
Proline | 1 | 2021 | 455 | 0.170 |
Why?
|
Lactams, Macrocyclic | 1 | 2021 | 318 | 0.170 |
Why?
|
Quinoxalines | 1 | 2021 | 296 | 0.160 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 529 | 0.150 |
Why?
|
Female | 23 | 2024 | 392148 | 0.150 |
Why?
|
Plant Oils | 1 | 2019 | 198 | 0.150 |
Why?
|
Adult | 17 | 2024 | 220969 | 0.150 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5812 | 0.140 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2018 | 128 | 0.140 |
Why?
|
Liver Failure, Acute | 1 | 2019 | 181 | 0.140 |
Why?
|
Fatty Liver | 2 | 2024 | 787 | 0.140 |
Why?
|
Telangiectasia, Hereditary Hemorrhagic | 1 | 2019 | 141 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 250 | 0.140 |
Why?
|
Aged | 14 | 2024 | 169042 | 0.140 |
Why?
|
Guanine | 1 | 2018 | 278 | 0.140 |
Why?
|
Hepatitis, Alcoholic | 1 | 2018 | 109 | 0.130 |
Why?
|
Viremia | 1 | 2019 | 707 | 0.130 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14591 | 0.130 |
Why?
|
Quinolines | 1 | 2021 | 764 | 0.130 |
Why?
|
Treatment Outcome | 12 | 2022 | 64568 | 0.130 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2013 | 1116 | 0.130 |
Why?
|
Time Factors | 9 | 2023 | 39913 | 0.130 |
Why?
|
Heart Diseases | 2 | 2018 | 2778 | 0.120 |
Why?
|
Signal Transduction | 3 | 2014 | 23416 | 0.120 |
Why?
|
Risk Factors | 11 | 2023 | 74115 | 0.120 |
Why?
|
Survival Rate | 5 | 2019 | 12719 | 0.120 |
Why?
|
HIV Infections | 1 | 2021 | 17337 | 0.120 |
Why?
|
Immunoglobulins | 1 | 2018 | 850 | 0.120 |
Why?
|
Area Under Curve | 1 | 2018 | 1635 | 0.120 |
Why?
|
Cadaver | 1 | 2018 | 1358 | 0.120 |
Why?
|
Hematinics | 1 | 2017 | 282 | 0.110 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 1 | 2014 | 100 | 0.110 |
Why?
|
Severity of Illness Index | 3 | 2022 | 15828 | 0.110 |
Why?
|
Maleimides | 1 | 2014 | 112 | 0.110 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1624 | 0.110 |
Why?
|
Neoplasm Invasiveness | 2 | 2018 | 3593 | 0.110 |
Why?
|
Irritable Bowel Syndrome | 1 | 2019 | 452 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2022 | 7389 | 0.110 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2014 | 296 | 0.110 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 2849 | 0.100 |
Why?
|
Blood Transfusion | 2 | 2017 | 1299 | 0.100 |
Why?
|
Duodenal Neoplasms | 1 | 2013 | 114 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2024 | 6474 | 0.100 |
Why?
|
Microvessels | 1 | 2016 | 577 | 0.100 |
Why?
|
Ultrasonography, Doppler | 1 | 2014 | 462 | 0.100 |
Why?
|
Hepatic Artery | 1 | 2013 | 232 | 0.100 |
Why?
|
Postoperative Complications | 3 | 2019 | 15612 | 0.100 |
Why?
|
Drug Combinations | 1 | 2018 | 2048 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1977 | 0.090 |
Why?
|
Postoperative Care | 1 | 2018 | 1467 | 0.090 |
Why?
|
Young Adult | 4 | 2024 | 59179 | 0.090 |
Why?
|
Esophageal and Gastric Varices | 1 | 2013 | 207 | 0.090 |
Why?
|
Prognosis | 3 | 2019 | 29600 | 0.090 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7798 | 0.090 |
Why?
|
Arteriovenous Fistula | 1 | 2013 | 319 | 0.080 |
Why?
|
Preoperative Care | 1 | 2018 | 2241 | 0.080 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 26049 | 0.080 |
Why?
|
Medically Uninsured | 1 | 2015 | 835 | 0.080 |
Why?
|
Administration, Oral | 1 | 2017 | 4010 | 0.080 |
Why?
|
Cholangiocarcinoma | 1 | 2014 | 552 | 0.080 |
Why?
|
Colonoscopy | 1 | 2017 | 1396 | 0.080 |
Why?
|
Bile Duct Neoplasms | 1 | 2014 | 605 | 0.080 |
Why?
|
Analgesics, Non-Narcotic | 2 | 2010 | 370 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2756 | 0.080 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2008 | 146 | 0.070 |
Why?
|
Biopsy | 2 | 2017 | 6762 | 0.070 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2827 | 0.070 |
Why?
|
Genotype | 1 | 2021 | 12978 | 0.070 |
Why?
|
Insurance, Health | 2 | 2017 | 2495 | 0.070 |
Why?
|
Comorbidity | 1 | 2020 | 10505 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10754 | 0.060 |
Why?
|
Survival Analysis | 1 | 2018 | 10073 | 0.060 |
Why?
|
Graft Rejection | 1 | 2019 | 4446 | 0.060 |
Why?
|
Indoles | 1 | 2014 | 1830 | 0.060 |
Why?
|
Heart Ventricles | 1 | 2018 | 3796 | 0.060 |
Why?
|
Cells, Cultured | 2 | 2014 | 18937 | 0.060 |
Why?
|
Echocardiography | 1 | 2018 | 4987 | 0.060 |
Why?
|
Pregnancy Complications | 1 | 2019 | 2948 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15251 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11069 | 0.060 |
Why?
|
Adolescent | 3 | 2024 | 88234 | 0.060 |
Why?
|
Mice, Inbred C57BL | 3 | 2014 | 22115 | 0.060 |
Why?
|
Age Factors | 1 | 2020 | 18381 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11116 | 0.060 |
Why?
|
Ferrochelatase | 1 | 2023 | 47 | 0.060 |
Why?
|
Models, Immunological | 1 | 2006 | 512 | 0.050 |
Why?
|
Isoenzymes | 1 | 2008 | 1687 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2015 | 1937 | 0.050 |
Why?
|
Glutathione | 1 | 2006 | 582 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39063 | 0.050 |
Why?
|
Cohort Studies | 2 | 2023 | 41457 | 0.050 |
Why?
|
Databases, Factual | 3 | 2024 | 7960 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2013 | 1653 | 0.050 |
Why?
|
Stomach Neoplasms | 1 | 2013 | 1453 | 0.050 |
Why?
|
Kidney Transplantation | 1 | 2018 | 4236 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5672 | 0.050 |
Why?
|
Incidence | 1 | 2020 | 21337 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2008 | 3591 | 0.050 |
Why?
|
Cholangitis, Sclerosing | 1 | 2023 | 177 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2021 | 18221 | 0.050 |
Why?
|
Secondary Prevention | 2 | 2018 | 1469 | 0.050 |
Why?
|
Reactive Oxygen Species | 2 | 2006 | 2137 | 0.050 |
Why?
|
Risk Assessment | 2 | 2021 | 23972 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11736 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8645 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20074 | 0.040 |
Why?
|
Cardiac Output, High | 1 | 2019 | 6 | 0.040 |
Why?
|
Phosphorylation | 2 | 2008 | 8311 | 0.040 |
Why?
|
Mice | 5 | 2021 | 81368 | 0.040 |
Why?
|
Mentha piperita | 1 | 2019 | 17 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2008 | 2456 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 12966 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 717 | 0.040 |
Why?
|
Aged, 80 and over | 1 | 2024 | 58894 | 0.040 |
Why?
|
Tumor Escape | 1 | 2021 | 371 | 0.040 |
Why?
|
Drug Synergism | 1 | 2021 | 1755 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5430 | 0.040 |
Why?
|
Hepatitis B Antibodies | 1 | 2018 | 155 | 0.040 |
Why?
|
Ventricular Pressure | 1 | 2018 | 210 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2008 | 2878 | 0.030 |
Why?
|
Patient Selection | 2 | 2019 | 4237 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2018 | 293 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20556 | 0.030 |
Why?
|
Animals | 7 | 2021 | 168201 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2509 | 0.030 |
Why?
|
Child | 1 | 2024 | 80079 | 0.030 |
Why?
|
Ventricular Function, Left | 2 | 2019 | 3873 | 0.030 |
Why?
|
Chemoprevention | 1 | 2018 | 325 | 0.030 |
Why?
|
Virus Activation | 1 | 2017 | 320 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2006 | 4341 | 0.030 |
Why?
|
Mitochondria | 1 | 2008 | 3619 | 0.030 |
Why?
|
Fibrosis | 1 | 2021 | 2045 | 0.030 |
Why?
|
Intraoperative Care | 1 | 2018 | 767 | 0.030 |
Why?
|
Ventricular Function, Right | 1 | 2018 | 617 | 0.030 |
Why?
|
Immunity, Innate | 1 | 2006 | 3045 | 0.030 |
Why?
|
Substance Abuse, Intravenous | 1 | 2018 | 529 | 0.030 |
Why?
|
Hematemesis | 1 | 2013 | 22 | 0.030 |
Why?
|
Arteries | 1 | 2018 | 1122 | 0.030 |
Why?
|
Postoperative Period | 1 | 2018 | 1813 | 0.030 |
Why?
|
Eligibility Determination | 1 | 2017 | 421 | 0.030 |
Why?
|
Hemostasis, Endoscopic | 1 | 2013 | 41 | 0.030 |
Why?
|
Phlebography | 1 | 2013 | 326 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12043 | 0.020 |
Why?
|
Mass Screening | 2 | 2018 | 5424 | 0.020 |
Why?
|
Apoptosis | 1 | 2006 | 9476 | 0.020 |
Why?
|
Biotransformation | 1 | 2010 | 166 | 0.020 |
Why?
|
Oxidation-Reduction | 2 | 2006 | 2231 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2024 | 12447 | 0.020 |
Why?
|
Cross Infection | 1 | 2018 | 1422 | 0.020 |
Why?
|
Recovery of Function | 1 | 2019 | 2978 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4845 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3868 | 0.020 |
Why?
|
Anthracenes | 1 | 2008 | 83 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7237 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2015 | 1723 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3351 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2015 | 2697 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 36402 | 0.020 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2013 | 872 | 0.020 |
Why?
|
Antimycin A | 1 | 2006 | 31 | 0.020 |
Why?
|
Caspase 7 | 1 | 2006 | 50 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8516 | 0.020 |
Why?
|
Carmustine | 1 | 2006 | 137 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16967 | 0.010 |
Why?
|
Poisoning | 1 | 2006 | 252 | 0.010 |
Why?
|
Stroke Volume | 1 | 2018 | 5486 | 0.010 |
Why?
|
Caspase 3 | 1 | 2006 | 731 | 0.010 |
Why?
|
Embolization, Therapeutic | 1 | 2013 | 1418 | 0.010 |
Why?
|
Caspases | 1 | 2006 | 878 | 0.010 |
Why?
|
Protein Transport | 1 | 2008 | 1966 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2010 | 2202 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13245 | 0.010 |
Why?
|
Oxygen Consumption | 1 | 2008 | 1866 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22148 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14018 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12933 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4007 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2016 | 11514 | 0.010 |
Why?
|
Blotting, Western | 1 | 2006 | 5034 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 3705 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29868 | 0.010 |
Why?
|
Heart Failure | 1 | 2019 | 11669 | 0.010 |
Why?
|
Oxygen | 1 | 2006 | 4226 | 0.010 |
Why?
|
Hospitalization | 1 | 2013 | 10704 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9461 | 0.010 |
Why?
|
Cytokines | 1 | 2006 | 7373 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11874 | 0.000 |
Why?
|
Concepts
(257)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_